ID   IL23R_HUMAN             Reviewed;         629 AA.
AC   Q5VWK5; C9JGX4; Q4VGP1; Q4VGP2; Q4VGP3; Q4VGP4; Q4VGP5; Q4VGP6; Q5VWK7;
AC   Q8IW84; Q8NFQ9; Q96AS1;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 3.
DT   28-JAN-2026, entry version 168.
DE   RecName: Full=Interleukin-23 receptor;
DE            Short=IL-23 receptor;
DE            Short=IL-23R;
DE   Flags: Precursor;
GN   Name=IL23R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH IL23;
RP   IL12RB1; JAK2 AND STAT3, PHOSPHORYLATION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND VARIANT PRO-310.
RC   TISSUE=Natural killer cell, and T-cell;
RX   PubMed=12023369; DOI=10.4049/jimmunol.168.11.5699;
RA   Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J.,
RA   Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J.,
RA   O'Farrell A.-M., McClanahan T.K., Zurawski S., Hannum C., Gorman D.,
RA   Rennick D.M., Kastelein R.A., de Waal Malefyt R., Moore K.W.;
RT   "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1
RT   and a novel cytokine receptor subunit, IL-23R.";
RL   J. Immunol. 168:5699-5708(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 5), NUCLEOTIDE SEQUENCE [MRNA]
RP   OF 37-629 (ISOFORMS 1; 3 AND 4), TISSUE SPECIFICITY, AND VARIANT PRO-310.
RC   TISSUE=Bone marrow;
RX   PubMed=16372191; DOI=10.1007/s00251-005-0067-0;
RA   Zhang X.-Y., Zhang H.-J., Zhang Y., Fu Y.-J., He J., Zhu L.-P., Wang S.-H.,
RA   Liu L.;
RT   "Identification and expression analysis of alternatively spliced isoforms
RT   of human interleukin-23 receptor gene in normal lymphoid cells and selected
RT   tumor cells.";
RL   Immunogenetics 57:934-943(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 7), AND VARIANT
RP   PRO-310.
RC   TISSUE=Bone marrow, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INVOLVEMENT IN IBD17, VARIANTS HIS-3; PRO-310 AND GLN-381, AND
RP   CHARACTERIZATION OF VARIANT GLN-381.
RX   PubMed=17068223; DOI=10.1126/science.1135245;
RA   Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S.,
RA   Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A.,
RA   Dassopoulos T., Bitton A., Yang H., Targan S., Datta L.W., Kistner E.O.,
RA   Schumm L.P., Lee A.T., Gregersen P.K., Barmada M.M., Rotter J.I.,
RA   Nicolae D.L., Cho J.H.;
RT   "A genome-wide association study identifies IL23R as an inflammatory bowel
RT   disease gene.";
RL   Science 314:1461-1463(2006).
RN   [6]
RP   VARIANT GLN-381, AND CHARACTERIZATION OF VARIANT GLN-381.
RX   PubMed=17587057; DOI=10.1007/s00439-007-0397-0;
RA   Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L.,
RA   Timms K., Gutin A., Abkevic V., Burden A.D., Lanchbury J., Barker J.N.,
RA   Trembath R.C., Nestle F.O.;
RT   "Sequence variants in the genes for the interleukin-23 receptor (IL23R) and
RT   its ligand (IL12B) confer protection against psoriasis.";
RL   Hum. Genet. 122:201-206(2007).
RN   [7]
RP   INVOLVEMENT IN IBD17, AND VARIANT GLN-381.
RX   PubMed=17804789; DOI=10.1073/pnas.0706645104;
RA   Raelson J.V., Little R.D., Ruether A., Fournier H., Paquin B.,
RA   Van Eerdewegh P., Bradley W.E.C., Croteau P., Nguyen-Huu Q., Segal J.,
RA   Debrus S., Allard R., Rosenstiel P., Franke A., Jacobs G., Nikolaus S.,
RA   Vidal J.-M., Szego P., Laplante N., Clark H.F., Paulussen R.J.,
RA   Hooper J.W., Keith T.P., Belouchi A., Schreiber S.;
RT   "Genome-wide association study for Crohn's disease in the Quebec founder
RT   population identifies multiple validated disease loci.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:14747-14752(2007).
RN   [8]
RP   VARIANTS PRO-310 AND GLN-381, AND CHARACTERIZATION OF VARIANT GLN-381.
RX   PubMed=18800148; DOI=10.1038/jid.2008.233;
RA   Huffmeier U., Lascorz J., Bohm B., Lohmann J., Wendler J., Mossner R.,
RA   Reich K., Traupe H., Kurrat W., Burkhardt H., Reis A.;
RT   "Genetic variants of the IL-23R pathway: association with psoriatic
RT   arthritis and psoriasis vulgaris, but no specific risk factor for
RT   arthritis.";
RL   J. Invest. Dermatol. 129:355-358(2009).
RN   [9]
RP   GLYCOSYLATION AT ASN-29; ASN-47; ASN-81; ASN-141; ASN-180; ASN-232; ASN-262
RP   AND ASN-273.
RX   PubMed=21053369; DOI=10.1002/jms.1858;
RA   Zhao J., Liu Y.H., Reichert P., Pflanz S., Pramanik B.;
RT   "Glycosylation analysis of interleukin-23 receptor: elucidation of
RT   glycosylation sites and characterization of attached glycan structures.";
RL   J. Mass Spectrom. 45:1416-1425(2010).
CC   -!- FUNCTION: Associates with IL12RB1 to form the interleukin-23 receptor.
CC       Binds IL23 and mediates T-cells, NK cells and possibly certain
CC       macrophage/myeloid cells stimulation probably through activation of the
CC       Jak-Stat signaling cascade. IL23 functions in innate and adaptive
CC       immunity and may participate in acute response to infection in
CC       peripheral tissues. IL23 may be responsible for autoimmune inflammatory
CC       diseases and be important for tumorigenesis.
CC       {ECO:0000269|PubMed:12023369}.
CC   -!- SUBUNIT: Heterodimer with IL12RB1. In presence of IL23, the heterodimer
CC       forms the IL23 receptor. Interacts with JAK2 and in presence of IL23
CC       with STAT3. {ECO:0000269|PubMed:12023369}.
CC   -!- INTERACTION:
CC       Q5VWK5; Q13901: C1D; NbExp=3; IntAct=EBI-10248005, EBI-3844053;
CC       Q5VWK5; Q9NPF7: IL23A; NbExp=2; IntAct=EBI-10248005, EBI-2481154;
CC       Q5VWK5; Q62120: Jak2; Xeno; NbExp=2; IntAct=EBI-10248005, EBI-646604;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12023369};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:12023369}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=IL-23R1;
CC         IsoId=Q5VWK5-1; Sequence=Displayed;
CC       Name=2; Synonyms=IL-23R2-F2;
CC         IsoId=Q5VWK5-2; Sequence=VSP_021993;
CC       Name=3; Synonyms=IL-23R3-F1;
CC         IsoId=Q5VWK5-3; Sequence=VSP_021997, VSP_021998;
CC       Name=4; Synonyms=IL-23R2-F1;
CC         IsoId=Q5VWK5-4; Sequence=VSP_021994, VSP_021995;
CC       Name=5; Synonyms=IL-23R3-F3;
CC         IsoId=Q5VWK5-5; Sequence=VSP_021991, VSP_021999;
CC       Name=6; Synonyms=IL-23R6;
CC         IsoId=Q5VWK5-6; Sequence=VSP_021992, VSP_021996;
CC       Name=7; Synonyms=IL-23R5;
CC         IsoId=Q5VWK5-7; Sequence=VSP_021990;
CC   -!- TISSUE SPECIFICITY: Expressed by monocytes, Th1, Th0, NK and dendritic
CC       cells. Isoform 1 is specifically expressed in NK cells.
CC       {ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:16372191}.
CC   -!- PTM: Phosphorylated in response to IL23. {ECO:0000269|PubMed:12023369}.
CC   -!- DISEASE: Inflammatory bowel disease 17 (IBD17) [MIM:612261]: A chronic,
CC       relapsing inflammation of the gastrointestinal tract with a complex
CC       etiology. It is subdivided into Crohn disease and ulcerative colitis
CC       phenotypes. Crohn disease may affect any part of the gastrointestinal
CC       tract from the mouth to the anus, but most frequently it involves the
CC       terminal ileum and colon. Bowel inflammation is transmural and
CC       discontinuous; it may contain granulomas or be associated with
CC       intestinal or perianal fistulas. In contrast, in ulcerative colitis,
CC       the inflammation is continuous and limited to rectal and colonic
CC       mucosal layers; fistulas and granulomas are not observed. Both diseases
CC       include extraintestinal inflammation of the skin, eyes, or joints.
CC       {ECO:0000269|PubMed:17068223, ECO:0000269|PubMed:17804789}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by translation in an alternate
CC       frame of the cDNA encoding isoform 4. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by translation in an alternate
CC       frame of the cDNA encoding isoform 5. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by translation in an alternate
CC       frame of the cDNA encoding isoform 2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by translation in an alternate
CC       frame of the cDNA encoding isoform 3. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 2
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH16829.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF461422; AAM44229.1; -; mRNA.
DR   EMBL; AY937250; AAY18345.1; -; mRNA.
DR   EMBL; AY937251; AAY18346.1; -; mRNA.
DR   EMBL; AY937252; AAY18347.1; -; mRNA.
DR   EMBL; AY937253; AAY18348.1; -; mRNA.
DR   EMBL; AY937254; AAY18349.1; -; mRNA.
DR   EMBL; AY937255; AAY18350.1; -; mRNA.
DR   EMBL; AL109843; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL389925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016829; AAH16829.1; ALT_INIT; mRNA.
DR   EMBL; BC040720; AAH40720.1; -; mRNA.
DR   CCDS; CCDS637.1; -. [Q5VWK5-1]
DR   RefSeq; NP_653302.2; NM_144701.2. [Q5VWK5-1]
DR   RefSeq; XP_011539092.1; XM_011540790.4. [Q5VWK5-1]
DR   RefSeq; XP_011539093.1; XM_011540791.4. [Q5VWK5-1]
DR   RefSeq; XP_054190613.1; XM_054334638.1. [Q5VWK5-1]
DR   RefSeq; XP_054190614.1; XM_054334639.1. [Q5VWK5-1]
DR   PDB; 5MZV; X-ray; 2.80 A; C=1-317.
DR   PDB; 6WDQ; X-ray; 3.40 A; C=24-317.
DR   PDB; 8OE4; EM; 3.60 A; C=24-353.
DR   PDB; 9MFG; X-ray; 2.85 A; A/B/C/D=25-317.
DR   PDBsum; 5MZV; -.
DR   PDBsum; 6WDQ; -.
DR   PDBsum; 8OE4; -.
DR   PDBsum; 9MFG; -.
DR   AlphaFoldDB; Q5VWK5; -.
DR   EMDB; EMD-21646; -.
DR   SMR; Q5VWK5; -.
DR   BioGRID; 127199; 15.
DR   ComplexPortal; CPX-383; Interleukin-23 receptor-ligand complex.
DR   CORUM; Q5VWK5; -.
DR   FunCoup; Q5VWK5; 389.
DR   IntAct; Q5VWK5; 10.
DR   STRING; 9606.ENSP00000321345; -.
DR   BindingDB; Q5VWK5; -.
DR   ChEMBL; CHEMBL4296013; -.
DR   GlyCosmos; Q5VWK5; 8 sites, No reported glycans.
DR   GlyGen; Q5VWK5; 9 sites.
DR   iPTMnet; Q5VWK5; -.
DR   PhosphoSitePlus; Q5VWK5; -.
DR   BioMuta; IL23R; -.
DR   DMDM; 311033431; -.
DR   jPOST; Q5VWK5; -.
DR   MassIVE; Q5VWK5; -.
DR   PaxDb; 9606-ENSP00000321345; -.
DR   PeptideAtlas; Q5VWK5; -.
DR   ProteomicsDB; 65533; -. [Q5VWK5-1]
DR   ProteomicsDB; 65535; -. [Q5VWK5-3]
DR   ProteomicsDB; 65536; -. [Q5VWK5-4]
DR   ProteomicsDB; 65539; -. [Q5VWK5-7]
DR   ABCD; Q5VWK5; 3 sequenced antibodies.
DR   Antibodypedia; 33405; 548 antibodies from 34 providers.
DR   DNASU; 149233; -.
DR   Ensembl; ENST00000347310.10; ENSP00000321345.5; ENSG00000162594.17. [Q5VWK5-1]
DR   Ensembl; ENST00000425614.3; ENSP00000387640.2; ENSG00000162594.17. [Q5VWK5-6]
DR   Ensembl; ENST00000697149.1; ENSP00000513138.1; ENSG00000162594.17. [Q5VWK5-4]
DR   Ensembl; ENST00000697150.1; ENSP00000513139.1; ENSG00000162594.17. [Q5VWK5-3]
DR   Ensembl; ENST00000697151.1; ENSP00000513140.1; ENSG00000162594.17. [Q5VWK5-3]
DR   Ensembl; ENST00000697153.1; ENSP00000513142.1; ENSG00000162594.17. [Q5VWK5-4]
DR   Ensembl; ENST00000697223.1; ENSP00000513190.1; ENSG00000162594.17. [Q5VWK5-4]
DR   Ensembl; ENST00000697224.1; ENSP00000513191.1; ENSG00000162594.17. [Q5VWK5-4]
DR   GeneID; 149233; -.
DR   KEGG; hsa:149233; -.
DR   MANE-Select; ENST00000347310.10; ENSP00000321345.5; NM_144701.3; NP_653302.2.
DR   UCSC; uc001ddo.4; human. [Q5VWK5-1]
DR   AGR; HGNC:19100; -.
DR   ClinPGx; PA134935109; -.
DR   CTD; 149233; -.
DR   DisGeNET; 149233; -.
DR   GeneCards; IL23R; -.
DR   HGNC; HGNC:19100; IL23R.
DR   HPA; ENSG00000162594; Tissue enhanced (adrenal gland, intestine, testis).
DR   MalaCards; IL23R; -.
DR   MIM; 607562; gene.
DR   MIM; 612261; phenotype.
DR   OpenTargets; ENSG00000162594; -.
DR   Orphanet; 117; Behcet disease.
DR   VEuPathDB; HostDB:ENSG00000162594; -.
DR   eggNOG; ENOG502QUIH; Eukaryota.
DR   GeneTree; ENSGT00530000064198; -.
DR   HOGENOM; CLU_029854_0_0_1; -.
DR   InParanoid; Q5VWK5; -.
DR   OMA; NWCHGGI; -.
DR   OrthoDB; 9897281at2759; -.
DR   PAN-GO; Q5VWK5; 7 GO annotations based on evolutionary models.
DR   PhylomeDB; Q5VWK5; -.
DR   PathwayCommons; Q5VWK5; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9020933; Interleukin-23 signaling.
DR   SignaLink; Q5VWK5; -.
DR   SIGNOR; Q5VWK5; -.
DR   Agora; ENSG00000162594; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 149233; 12 hits in 1147 CRISPR screens.
DR   ChiTaRS; IL23R; human.
DR   GeneWiki; Interleukin-23_receptor; -.
DR   GenomeRNAi; 149233; -.
DR   Pharos; Q5VWK5; Tchem.
DR   PRO; PR:Q5VWK5; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q5VWK5; protein.
DR   Bgee; ENSG00000162594; Expressed in secondary oocyte and 25 other cell types or tissues.
DR   ExpressionAtlas; Q5VWK5; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0072536; C:interleukin-23 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0019955; F:cytokine binding; IBA:GO_Central.
DR   GO; GO:0004896; F:cytokine receptor activity; IDA:UniProt.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0004925; F:prolactin receptor activity; IBA:GO_Central.
DR   GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IC:BHF-UCL.
DR   GO; GO:0097696; P:cell surface receptor signaling pathway via STAT; TAS:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IC:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0038155; P:interleukin-23-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; IMP:BHF-UCL.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IC:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:BHF-UCL.
DR   GO; GO:0032725; P:positive regulation of granulocyte macrophage colony-stimulating factor production; IC:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:BHF-UCL.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IC:BHF-UCL.
DR   GO; GO:0043382; P:positive regulation of memory T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0032819; P:positive regulation of natural killer cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0051135; P:positive regulation of NK T cell activation; TAS:BHF-UCL.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IC:BHF-UCL.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; ISS:BHF-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IC:BHF-UCL.
DR   GO; GO:0002827; P:positive regulation of T-helper 1 type immune response; IDA:BHF-UCL.
DR   GO; GO:2000330; P:positive regulation of T-helper 17 cell lineage commitment; ISS:BHF-UCL.
DR   GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISS:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of type II interferon production; IDA:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:BHF-UCL.
DR   GO; GO:0034341; P:response to type II interferon; IDA:BHF-UCL.
DR   FunFam; 2.60.40.10:FF:001364; Interleukin 23 receptor; 1.
DR   FunFam; 2.60.40.10:FF:001392; Interleukin 23 receptor; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR052672; Type1_Cytokine_Rcpt_Type2.
DR   PANTHER; PTHR48423:SF2; INTERLEUKIN-12 RECEPTOR SUBUNIT BETA-2; 1.
DR   PANTHER; PTHR48423; INTERLEUKIN-27 RECEPTOR SUBUNIT ALPHA; 1.
DR   SUPFAM; SSF49265; Fibronectin type III; 2.
DR   PROSITE; PS50853; FN3; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Membrane; Phosphoprotein;
KW   Proteomics identification; Receptor; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..629
FT                   /note="Interleukin-23 receptor"
FT                   /id="PRO_0000268662"
FT   TOPO_DOM        24..355
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        356..376
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        377..629
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          127..217
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          219..318
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   CARBOHYD        29
FT                   /note="N-linked (GlcNAc...) asparagine; partial"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        47
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        81
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        141
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        180
FT                   /note="N-linked (GlcNAc...) (high mannose) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        232
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        262
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   CARBOHYD        273
FT                   /note="N-linked (GlcNAc...) asparagine; partial"
FT                   /evidence="ECO:0000269|PubMed:21053369"
FT   VAR_SEQ         1..402
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021990"
FT   VAR_SEQ         1..365
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021991"
FT   VAR_SEQ         1..255
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021992"
FT   VAR_SEQ         1..254
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021993"
FT   VAR_SEQ         165..174
FT                   /note="LETEEEQQYL -> DTFCSRHFQG (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021994"
FT   VAR_SEQ         175..629
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021995"
FT   VAR_SEQ         256..266
FT                   /note="RYKATTNQTWN -> MILRPYQPCGT (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021996"
FT   VAR_SEQ         349..356
FT                   /note="DNRGDIGL -> GLKEGSYC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021997"
FT   VAR_SEQ         357..629
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021998"
FT   VAR_SEQ         366..383
FT                   /note="MLSILSLIGIFNRSFRTG -> MEFWANSCFHLYRAPYFW (in isoform
FT                   5)"
FT                   /evidence="ECO:0000303|PubMed:16372191"
FT                   /id="VSP_021999"
FT   VARIANT         3
FT                   /note="Q -> H (in dbSNP:rs1884444)"
FT                   /evidence="ECO:0000269|PubMed:17068223"
FT                   /id="VAR_029752"
FT   VARIANT         175
FT                   /note="T -> N (in dbSNP:rs11465797)"
FT                   /id="VAR_047955"
FT   VARIANT         310
FT                   /note="L -> P (in dbSNP:rs7530511)"
FT                   /evidence="ECO:0000269|PubMed:12023369,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:16372191,
FT                   ECO:0000269|PubMed:17068223, ECO:0000269|PubMed:18800148"
FT                   /id="VAR_029753"
FT   VARIANT         381
FT                   /note="R -> Q (protective factor against IBD17; protective
FT                   factor against psoriasis; dbSNP:rs11209026)"
FT                   /evidence="ECO:0000269|PubMed:17068223,
FT                   ECO:0000269|PubMed:17587057, ECO:0000269|PubMed:17804789,
FT                   ECO:0000269|PubMed:18800148"
FT                   /id="VAR_029754"
FT   CONFLICT        46
FT                   /note="M -> T (in Ref. 2; AAY18346)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        133
FT                   /note="C -> R (in Ref. 2; AAY18348)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        302
FT                   /note="R -> G (in Ref. 2; AAY18348)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        475
FT                   /note="V -> A (in Ref. 2; AAY18347)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        481
FT                   /note="N -> D (in Ref. 2; AAY18347)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        581
FT                   /note="S -> R (in Ref. 2; AAY18349)"
FT                   /evidence="ECO:0000305"
FT   STRAND          31..38
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          40..43
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          48..54
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          64..68
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          75..81
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          84..91
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          95..104
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          109..122
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          129..136
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:6WDQ"
FT   STRAND          141..147
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          157..164
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   TURN            165..167
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          170..177
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          179..182
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          190..200
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          203..206
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          210..213
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   TURN            214..216
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          217..219
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          223..230
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          233..235
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          237..244
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          249..259
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          266..270
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          278..283
FT                   /evidence="ECO:0007829|PDB:5MZV"
FT   STRAND          290..298
FT                   /evidence="ECO:0007829|PDB:5MZV"
SQ   SEQUENCE   629 AA;  71722 MW;  AC63C89E81AABF05 CRC64;
     MNQVTIQWDA VIALYILFSW CHGGITNINC SGHIWVEPAT IFKMGMNISI YCQAAIKNCQ
     PRKLHFYKNG IKERFQITRI NKTTARLWYK NFLEPHASMY CTAECPKHFQ ETLICGKDIS
     SGYPPDIPDE VTCVIYEYSG NMTCTWNAGK LTYIDTKYVV HVKSLETEEE QQYLTSSYIN
     ISTDSLQGGK KYLVWVQAAN ALGMEESKQL QIHLDDIVIP SAAVISRAET INATVPKTII
     YWDSQTTIEK VSCEMRYKAT TNQTWNVKEF DTNFTYVQQS EFYLEPNIKY VFQVRCQETG
     KRYWQPWSSL FFHKTPETVP QVTSKAFQHD TWNSGLTVAS ISTGHLTSDN RGDIGLLLGM
     IVFAVMLSIL SLIGIFNRSF RTGIKRRILL LIPKWLYEDI PNMKNSNVVK MLQENSELMN
     NNSSEQVLYV DPMITEIKEI FIPEHKPTDY KKENTGPLET RDYPQNSLFD NTTVVYIPDL
     NTGYKPQISN FLPEGSHLSN NNEITSLTLK PPVDSLDSGN NPRLQKHPNF AFSVSSVNSL
     SNTIFLGELS LILNQGECSS PDIQNSVEEE TTMLLENDSP SETIPEQTLL PDEFVSCLGI
     VNEELPSINT YFPQNILESH FNRISLLEK
//
